Latest IKCS News
‘We’re Not There Yet’: CAR T-Cell Therapy for Renal Cell Carcinoma
NASHVILLE, Tenn. -- Chimeric antigen receptor (CAR) T-cell therapy has the potential…
Targeting New Pathways to Improve Outcomes in Renal Cell Carcinoma
NASHVILLE, Tenn. -- Building on the existing immune checkpoint inhibitor (ICI) platform,…
No Boost in Outcomes for Clear Cell RCC With Higher Belzutifan Dose
NASHVILLE, Tenn. -- A higher dose of belzutifan (Welireg) being investigated for…
Tyrosine Kinase Inhibitor Active in Heavily Treated Renal Cell Carcinoma
NASHVILLE, Tenn. -- An investigational multitargeted drug produced objective responses in clear-cell…
